<p>Lenvatinib is a kinase inhibitor that is indicated:</p>

<ul>
	<li><strong>Differentiated Thyroid Cancer</strong>: Lenvatinib is indicated for the treatment of patients with locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer (DTC).</li>
	<li><strong>Renal Cell Carcinoma</strong>: Lenvatinib is indicated in combination with Everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) following one prior anti-angiogenic therapy.</li>
	<li><strong>Hepatocellular Carcinoma</strong>: Lenvatinib is indicated for the first-line treatment of patients with unresectable hepatocellular carcinoma (HCC).</li>
	<li><strong>Endometrial Carcinoma</strong>: Lenvatinib, in combination with Pembrolizumab, is indicated for the treatment of patients with advanced endometrial carcinoma that is not microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR), who have disease progression following prior systemic therapy and are not candidates for curative surgery or radiation.</li>
</ul>